论文部分内容阅读
目的探讨腹膜透析与血液透析患者血浆胃促生长素(Ghrelin)水平。方法选取2013年2月至2015年8月广东省汕头市汕头大学医学院第一附属医院接诊的腹膜透析患者30例(腹膜组)、血液透析患者30例(血液组)、健康体检者30例(对照组),检测所有入选对象血浆Ghrelin水平。结果治疗前,腹膜组与血液组患者血浆Ghrelin水平均明显高于对照组(均P<0.05),但腹膜组与血液组差异无统计学意义(P>0.05);治疗后,腹膜组与血液组患者血浆Ghrelin水平均明显低于对照组,差异均有统计学意义(均P<0.05),但组间比较差异无统计学意义(P>0.05)。结论血浆Ghrelin代谢主要场所为肾脏,不论是腹膜透析还是血液透析患者,体内血浆Ghrelin水平均明显高于正常人,但经透析治疗后血浆Ghrelin水平会显著降低,但依旧无法达到正常人群水平。
Objective To investigate the plasma level of ghrelin in peritoneal dialysis and hemodialysis patients. Methods Thirty patients (peritoneal group), 30 hemodialysis patients (blood group) and 30 healthy individuals (peritoneal dialysis group) were admitted to the First Affiliated Hospital of Shantou University Medical College from February 2013 to August 2015 in Shantou, Guangdong Province. Cases (control group), all subjects were tested for plasma Ghrelin levels. Results Before treatment, the levels of plasma Ghrelin in peritoneal group and blood group were significantly higher than those in control group (all P <0.05), but there was no significant difference between peritoneal group and blood group (P> 0.05) The plasma Ghrelin level of the patients in the two groups were significantly lower than that of the control group (all P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusions Plasma Ghrelin is the main site of kidney metabolism. Whether in peritoneal dialysis or hemodialysis patients, the level of plasma Ghrelin is significantly higher than that in normal subjects. However, the plasma Ghrelin level will be significantly reduced after dialysis treatment, but the level of Ghrelin still can not reach the normal level.